1. Home
  2. INSM vs WSO Comparison

INSM vs WSO Comparison

Compare INSM & WSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INSM
  • WSO
  • Stock Information
  • Founded
  • INSM 1988
  • WSO 1945
  • Country
  • INSM United States
  • WSO United States
  • Employees
  • INSM N/A
  • WSO N/A
  • Industry
  • INSM Biotechnology: Pharmaceutical Preparations
  • WSO Industrial Machinery/Components
  • Sector
  • INSM Health Care
  • WSO Consumer Discretionary
  • Exchange
  • INSM Nasdaq
  • WSO Nasdaq
  • Market Cap
  • INSM 17.3B
  • WSO 18.6B
  • IPO Year
  • INSM 2000
  • WSO N/A
  • Fundamental
  • Price
  • INSM $102.68
  • WSO $421.83
  • Analyst Decision
  • INSM Strong Buy
  • WSO Hold
  • Analyst Count
  • INSM 17
  • WSO 5
  • Target Price
  • INSM $106.80
  • WSO $478.75
  • AVG Volume (30 Days)
  • INSM 4.1M
  • WSO 272.3K
  • Earning Date
  • INSM 08-07-2025
  • WSO 07-29-2025
  • Dividend Yield
  • INSM N/A
  • WSO 2.84%
  • EPS Growth
  • INSM N/A
  • WSO 0.29
  • EPS
  • INSM N/A
  • WSO 13.03
  • Revenue
  • INSM $381,030,000.00
  • WSO $7,584,412,000.00
  • Revenue This Year
  • INSM $28.03
  • WSO $5.15
  • Revenue Next Year
  • INSM $120.54
  • WSO $5.27
  • P/E Ratio
  • INSM N/A
  • WSO $32.39
  • Revenue Growth
  • INSM 20.77
  • WSO 3.92
  • 52 Week Low
  • INSM $60.40
  • WSO $419.94
  • 52 Week High
  • INSM $102.70
  • WSO $571.42
  • Technical
  • Relative Strength Index (RSI)
  • INSM 78.76
  • WSO 31.04
  • Support Level
  • INSM $98.46
  • WSO $422.99
  • Resistance Level
  • INSM $102.00
  • WSO $451.52
  • Average True Range (ATR)
  • INSM 3.50
  • WSO 8.87
  • MACD
  • INSM 2.61
  • WSO -1.40
  • Stochastic Oscillator
  • INSM 99.61
  • WSO 6.09

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

About WSO Watsco Inc.

Watsco is the largest heating, ventilation, air conditioning, and refrigeration products distributor in North America. The company primarily operates in the United States (90% of revenue) with significant exposure in the Sunbelt states. Watsco also has operations in Canada (5% of sales) and Latin America (5% of sales). The company's customer base consists of more than 125,000 contractors that serve the replacement and new construction HVACR markets for residential and light commercial applications.

Share on Social Networks: